NOC as a Service Market Surges to $6.14 billion at a CAGR 10.5% by 2030 | Report by MarketsandMarkets™
GridAI Technologies Signs Definitive Agreement to Acquire Pronghorn Resources, Establishing Major Wyoming Owned-Natural Gas and Multi-Gigawatt AI Power Infrastructure Platform Targeting Initial Power Delivery in 2027
Satellite Propulsion Market to Reach USD 4.66 Billion by 2031, Driven by the Rapid Shift Toward Electric and Green Propulsion Systems
results
View All ->
Binah Capital Group Reports Results for Third Quarter of 2026
- Assets Under Management (“AuM”) Increased 5.0% Year-over-Year to $31.4 Billion - - Increased Net Income to $2.6 Million from net income of $1.8 million in the Prior Year Period - - Increased EBITDA [*] to $4.7 Million from $2.7 Million in the Prior Year Period - - Increased Total Revenue to $50.6 million from $46.2 million in prior year period - NEW YORK, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Binah Capital Group, Inc. (“Binah”, “Binah Capital” or the “Company”) (NASDAQ: BCG; BCGWW), a leading fina
Lifeward Reports Third Quarter 2026 Financial Results and Provides Business Update
AlterG revenue increased 18% year-over-year to $3.6 million, driven by higher U.S. unit shipments, service revenue and average selling prices The Company is advancing its transition of ReWalk to a capital-efficient channel-partner distribution model designed to expand patient access and support long-term revenue growth New leadership team focused on commercial execution and advancing AI-enabled rehabilitation technologies New peer-reviewed clinical evidence strengthens support for ReWalk’s long-
newsUPDATED -- Benitec Biopharma Releases First Quarter 2027 Fiscal-Year Financial Results and Provides Operational Update
Positive interim clinical results from the ongoing BB-301 Phase 1b/2a study for dysphagic patients with Oculopharyngeal Muscular Dystrophy (OPMD), presented as a late-breaking poster at the European Society of Gene and Cell Therapy (ESGCT) Annual Congress showed a 100% responder rate across all Cohort 1 (low dose) and Cohort 2 (high dose) patients BB-301 pivotal study design to be finalized in the first calendar quarter of 2027, and the company remains on track to begin the pivotal trial in mid-
quarter
View All ->Binah Capital Group Reports Results for Third Quarter of 2026
- Assets Under Management (“AuM”) Increased 5.0% Year-over-Year to $31.4 Billion - - Increased Net Income to $2.6 Million from net income of $1.8 million in the Prior Year Period - - Increased EBITDA [*] to $4.7 Million from $2.7 Million in the Prior Year Period - - Increased Total Revenue to $50.6 million from $46.2 million in prior year period - NEW YORK, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Binah Capital Group, Inc. (“Binah”, “Binah Capital” or the “Company”) (NASDAQ: BCG; BCGWW), a leading fina
Lifeward Reports Third Quarter 2026 Financial Results and Provides Business Update
AlterG revenue increased 18% year-over-year to $3.6 million, driven by higher U.S. unit shipments, service revenue and average selling prices The Company is advancing its transition of ReWalk to a capital-efficient channel-partner distribution model designed to expand patient access and support long-term revenue growth New leadership team focused on commercial execution and advancing AI-enabled rehabilitation technologies New peer-reviewed clinical evidence strengthens support for ReWalk’s long-
newsUPDATED -- Benitec Biopharma Releases First Quarter 2027 Fiscal-Year Financial Results and Provides Operational Update
Positive interim clinical results from the ongoing BB-301 Phase 1b/2a study for dysphagic patients with Oculopharyngeal Muscular Dystrophy (OPMD), presented as a late-breaking poster at the European Society of Gene and Cell Therapy (ESGCT) Annual Congress showed a 100% responder rate across all Cohort 1 (low dose) and Cohort 2 (high dose) patients BB-301 pivotal study design to be finalized in the first calendar quarter of 2027, and the company remains on track to begin the pivotal trial in mid-
third
View All ->Binah Capital Group Reports Results for Third Quarter of 2026
- Assets Under Management (“AuM”) Increased 5.0% Year-over-Year to $31.4 Billion - - Increased Net Income to $2.6 Million from net income of $1.8 million in the Prior Year Period - - Increased EBITDA [*] to $4.7 Million from $2.7 Million in the Prior Year Period - - Increased Total Revenue to $50.6 million from $46.2 million in prior year period - NEW YORK, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Binah Capital Group, Inc. (“Binah”, “Binah Capital” or the “Company”) (NASDAQ: BCG; BCGWW), a leading fina
Lifeward Reports Third Quarter 2026 Financial Results and Provides Business Update
AlterG revenue increased 18% year-over-year to $3.6 million, driven by higher U.S. unit shipments, service revenue and average selling prices The Company is advancing its transition of ReWalk to a capital-efficient channel-partner distribution model designed to expand patient access and support long-term revenue growth New leadership team focused on commercial execution and advancing AI-enabled rehabilitation technologies New peer-reviewed clinical evidence strengthens support for ReWalk’s long-
newsSilexion Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
First patient dosed in the Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center, moving SIL204 into active patient treatment New translational data expanded SIL204’s profile, including a coordinated immune-sensitization signature across four KRAS mutations and a native lipoprotein-mediated uptake mechanism that supports systemic administration Third quarter financings increased cash and cash equivalents to $4.8 million and shareholders’ equ
reports
View All ->Binah Capital Group Reports Results for Third Quarter of 2026
- Assets Under Management (“AuM”) Increased 5.0% Year-over-Year to $31.4 Billion - - Increased Net Income to $2.6 Million from net income of $1.8 million in the Prior Year Period - - Increased EBITDA [*] to $4.7 Million from $2.7 Million in the Prior Year Period - - Increased Total Revenue to $50.6 million from $46.2 million in prior year period - NEW YORK, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Binah Capital Group, Inc. (“Binah”, “Binah Capital” or the “Company”) (NASDAQ: BCG; BCGWW), a leading fina
Lifeward Reports Third Quarter 2026 Financial Results and Provides Business Update
AlterG revenue increased 18% year-over-year to $3.6 million, driven by higher U.S. unit shipments, service revenue and average selling prices The Company is advancing its transition of ReWalk to a capital-efficient channel-partner distribution model designed to expand patient access and support long-term revenue growth New leadership team focused on commercial execution and advancing AI-enabled rehabilitation technologies New peer-reviewed clinical evidence strengthens support for ReWalk’s long-
newsSilexion Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
First patient dosed in the Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center, moving SIL204 into active patient treatment New translational data expanded SIL204’s profile, including a coordinated immune-sensitization signature across four KRAS mutations and a native lipoprotein-mediated uptake mechanism that supports systemic administration Third quarter financings increased cash and cash equivalents to $4.8 million and shareholders’ equ
financial
View All ->
Lifeward Reports Third Quarter 2026 Financial Results and Provides Business Update
AlterG revenue increased 18% year-over-year to $3.6 million, driven by higher U.S. unit shipments, service revenue and average selling prices The Company is advancing its transition of ReWalk to a capital-efficient channel-partner distribution model designed to expand patient access and support long-term revenue growth New leadership team focused on commercial execution and advancing AI-enabled rehabilitation technologies New peer-reviewed clinical evidence strengthens support for ReWalk’s long-
UPDATED -- Benitec Biopharma Releases First Quarter 2027 Fiscal-Year Financial Results and Provides Operational Update
Positive interim clinical results from the ongoing BB-301 Phase 1b/2a study for dysphagic patients with Oculopharyngeal Muscular Dystrophy (OPMD), presented as a late-breaking poster at the European Society of Gene and Cell Therapy (ESGCT) Annual Congress showed a 100% responder rate across all Cohort 1 (low dose) and Cohort 2 (high dose) patients BB-301 pivotal study design to be finalized in the first calendar quarter of 2027, and the company remains on track to begin the pivotal trial in mid-
newsSilexion Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
First patient dosed in the Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center, moving SIL204 into active patient treatment New translational data expanded SIL204’s profile, including a coordinated immune-sensitization signature across four KRAS mutations and a native lipoprotein-mediated uptake mechanism that supports systemic administration Third quarter financings increased cash and cash equivalents to $4.8 million and shareholders’ equ
Magazine Focus
The New Growth Playbook: Building Businesses for Sustainable Expansion
Growth is being redefined. Expanding revenue remains important, but businesses are placing greater emphasis on profitability, cash discipline, operational efficiency, customer retention and resilience. This edition explores the changing growth playbook and the foundations required for sustainable expansion. From technology and process design to capital allocation and market reach, it examines how businesses can pursue ambition without allowing complexity, costs or uncontrolled expansion to weaken the enterprise.
For years, growth was often discussed primarily in terms of size, speed and market share. The conversation is becoming more balanced. Strong businesses also need healthy economics, efficient operations and the ability to withstand uncertainty. This edition looks at growth through that wider lens and considers how organizations can expand with greater discipline, clarity and long-term purpose in practice.
The day in focus. Delivered to your inbox.
A concise daily briefing of key stories, insights and developments, selected by our editorial team.
By subscribing, you agree to our Privacy Policy. Unsubscribe at any time.